Streetbeat News

Analyst Ratings

PEN

JP Morgan analyst Robbie Marcus downgrades Penumbra (NYSE:PEN) from Overweight to Neutral and lowers the price target from $284 to $250, indicating a more cautious outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 11:17 am

AAOI

B. Riley Securities analyst David Kang downgraded Applied Optoelectronics (AAOI) from Buy to Neutral and reduced the price target from $22 to $16.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 11:14 am

NTR

JP Morgan analyst Jeffrey Zekauskas downgraded Nutrien (NYSE:NTR) from Neutral to Underweight and reduced the price target from $58 to $48.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 11:11 am

NVDA

Jim Chanos, a notable short-seller, raised concerns about Nvidia Corp.'s (NASDAQ:NVDA) dependency on the Magnificent 7 companies for its operating cash flow, suggesting that most of it comes from their capital expenditures. This comes amid discussions on the sustainability of Nvidia's growth, fueled by the AI boom. Speculation exists around whether companies like Meta Platforms or Microsoft, significant Nvidia customers, will continue their high level of GPU spending. Nvidia's stock rose 2.03% in premarket trading following its strong Q4 results.

Portfolio Pulse from Shanthi Rexaline

February 23, 2024 | 11:09 am

MODV

Deutsche Bank analyst Pito Chickering downgraded ModivCare (NASDAQ:MODV) from Buy to Hold and reduced the price target from $60 to $40.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 11:06 am

PMTS

Roth MKM analyst Craig Irwin initiates coverage on CPI Card (NASDAQ:PMTS) with a Buy rating and sets a price target of $40.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 11:03 am

INCY

Jefferies analyst Kelly Shi initiates coverage on Incyte (NASDAQ:INCY) with a Buy rating and sets a price target of $81.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 10:54 am

ADEA

Rosenblatt analyst Kevin Cassidy initiates coverage on Adeia (NASDAQ:ADEA) with a Buy rating and a price target of $15.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 10:52 am

NUVL

Baird analyst Colleen Kusy initiates coverage on Nuvalent (NASDAQ:NUVL) with an Outperform rating and a price target of $105.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 10:50 am

PFE

Guggenheim analyst Vamil Divan has initiated coverage on Pfizer (NYSE:PFE) with a Buy rating and set a price target of $36.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 10:48 am